Company Profile - Sio Gene Therapies Inc

Introduction

Sio Gene Therapies Inc (Sio Gene) is a clinical-stage biopharmaceutical company that develops and commercializes novel medicines. The company develops medicines for the treatment of multiple forms of dementia and related neurological disorders. Sio Gene's pipeline products comprise AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2. The company’s AXO-Lenti-PD is a lentiviral gene therapy that contains three genes that encode the critical enzymes required for endogenous dopamine synthesis. It develops gene therapies for GM1 and GM2 gangliosidosis including Tay-Sachs disease and Sandhoff disease. The company has operations in North Carolina, the US. Sio Gene is headquartered in New York, the US.